Skip to main content

Drug Interactions between topotecan and vemurafenib

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

topotecan vemurafenib

Applies to: topotecan and vemurafenib

MONITOR: Coadministration with vemurafenib may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) transporters, such as dabigatran, rosuvastatin, sulfasazine, and topotecan. The proposed mechanism, based on in vitro data, is decreased clearance due to vemurafenib-mediated inhibition of P-gp and/or BCRP efflux transport proteins.

MANAGEMENT: Caution is advised if vemurafenib is used concomitantly with drugs that are substrates of P-gp and/or BCRP transport proteins, particularly those with a narrow therapeutic range. Some authorities suggest avoiding the use of vemurafenib with drugs that are substrates of these transport proteins and have a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever vemurafenib is added to or withdrawn from therapy with these drugs. Patients should be monitored for the development of adverse effects.

References (3)
  1. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  2. Cerner Multum, Inc. "Australian Product Information."
  3. (2011) "Product Information. Zelboraf (vemurafenib)." Genentech

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer